Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Easy Run to 55 Cents!!!
basically your only chance in getting any shares at a good value would be to put a higher legitimate bid that somebody would sell you their shares for, if you are trying to get your shares at .0006 that is not going to happen. A good Example would be 8 Cents on this security, you would have to put a bid for 5000 shares minimum at 8 cents, 5000 shares so your buy order will be visible for another investor to see your buy order and sell you their shares
Yeah i really dont know how it works, i've never played with stocks like this.
Lol, good luck filling a $2000 order at .0001, Not going to happen
I see what you are saying, however with such high gains, are you not still making a ton of money even if the commission costs will hurt because of multiple executions. Say I put in 2,000$ at .0001, and it gains 1,000%, that is around 20,000$ is it not? But i believe what you are saying is that I would not be able to buy 2000$ worth of shares at .0001 all together nor would I be able to sell at .01 for my gains, is that correct? Only some will be executed at that price?
Hey man thanks for the reply, I do not have nearly as much experience as you, and I was wondering if you can give me some advice about this stock. Im guessing you have been trading it, I was thinking about doing what i told you, but I am not sure if this will work since i have not actually done it yet. If i was to buy at .0001 and wait for it to hit its huge percentage increases that seem to occur a couple times a month, will i be able to sell right after these gains and take my 1000% or more? Im just wondering if you have done anything like this or with your much greater experience can give me some insight about how this stock works.
Thanks alot
That sounds like investment advice! LOL. I trade for a living wattar, but always looking for new tactics
THX Bud
The best thing to do with this stock by looking at the charts, is to buy at the lowest point .0001, and sell at .015, basically just buy and hold, wait for the huge gains, and sell, the best thing to do here. Trying to hold further then that, you will most likely loose.
Once we get Bid Support at .14 we'll Run to 55 Cents!!!!
The more I research the more I love this company
Share Structure on this stock is Incredible for these prices
I added you as board assistant, Awesome DD!
Also found this.
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 16,500,000 Ordinary Shares, nominal value NIS 0.01 per share
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=6678823
Here is what i found on pinks i assume highlighted is the form of AS.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of October, 2009
CELL KINETICS LTD.
(Translation of registrant’s name into English)
2 Yodfat Street
Lod 71219, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule12g3-2(b): 82- N/A
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Cell Kinetics Ltd. (the “Company”) hereby announces that at the Annual General Meeting of Shareholders held on October 13, 2009 (the “General Meeting”), all the proposed resolutions set forth in the proxy statement with respect to the General Meeting, filed under Form 6-K on August 9, 2009 (the “Proxy Statement”), were adopted, with the exception of Item 4 and part of Item 1, as follows:
1. To reelect Mr. Shmuel Peretz, Mr. Mitchell H. Freeman, Mr. Daniel A. Luchansky, and Ms. Jaclynn Fischman Shweky to serve on the Board of Directors (the “Board”) until the Company’s next annual general meeting of shareholders and until their successors have been duly elected and qualified. This resolution was approved as to Mr. Mitchell H. Freeman, Mr. Daniel A. Luchansky, and Ms. Jaclynn Fischman Shweky and not approved as to Mr. Shmuel Peretz.
2. To approve the compensation to our Directors who are not Company employees or consultants. This resolution was approved.
3. To approve a one time payment of $1,500 to Shmuel Peretz, Chairman of the Board, in addition to any other compensation received. This resolution was approved.
4. To authorize as compensation quarterly payments of up to $4,500 each to the presiding Chairman of the Board of the Company, such amounts to be determined by the Audit Committee and Board of Directors on a quarterly basis beginning November 1, 2009. Such amounts shall be in addition to the compensation referred to in Proposals 2 and 3. This resolution was not approved.
5. To approve the grant of options to purchase 25,000 Ordinary Shares of the Company, to be granted to the Company’s directors (excluding external directors). This resolution was approved.
6. To approve the grant of options to purchase 10,000 Ordinary Shares of the Company, to be granted to directors Shmuel Peretz and Mitchell Freeman, which shall be in addition to the options referred to in Proposal 5 above. This resolution was approved.
7. To increase the share capital of the Company such that following such increase the Company’s share capital shall be NIS 5,000,000 (five million New Israeli Shekels), divided into 500,000,000 (five hundred million) Ordinary Shares, nominal value NIS 0.01 each, and to amend the Company’s Articles of Association to reflect such increase of share capital. This resolution was approved.
8. To approve an extension of certain expiration dates for options held by all directors, excluding external directors. This resolution was approved.
9. To re-appoint Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the independent auditors of the Company for the year ending December 31, 2009 and for such additional period until the next Annual General Shareholders’ Meeting, and to authorize the Board to fix the remuneration of the independent auditors based on the volume and nature of their services in accordance with the Israeli Companies Law, 5759-1999. This resolution was approved.
Stock should be trading at Ten Dollar Range minimum with this share structure
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
17
|
Created
|
09/27/11
|
Type
|
Free
|
Moderators |
· | Dynamic Imaging in Living Cells |
· | Assessing Responses of Individual Cells |
· | Gene Expression and Genetic Engineering |
· | Microscopy , in which cells are held on a glass slide or in small wells in nutrient medium. Often groups of cells are held in a well in which they are free to move around in the microscopic field so that monitored cellular events reflect the average response of the group, rather than that of individual cells which may deviate far from the average. |
· | Flow methods are limited to analyzing cells in fluids and the recorded cells are often discarded after measurement; |
· | Cell-based assays requiring time resolution, such as enzyme kinetics or drug uptake and/or action, make no sense by flow methods as specific cells cannot be re-analyzed; |
· | It is difficult to use Flow cytometry to determine sub-cellular localization of fluorochromes employed to study intracellular events; |
· | Flow cytometry is impractical for small cell numbers; and |
· | Flow cytometry equipment is a high-priced tool ($50,000 - $500,000). |
· | Imaging adherent as well as non-adherent live cells; |
· | Revisiting and monitoring specific cells at designated "addresses;" |
· | Sequential manipulation of individual live cells; |
· | Potential retrieval of specific cells; and |
· | Simultaneous monitoring of kinetic data of multiple individual cells. |
· | ability to capture and register living cells at specific addresses; |
· | ability to monitor identifiable individual cells and rare events; |
· | ability to repeatedly monitor cells for acquisition of kinetic data; |
· | simultaneous and sequential monitoring of up to 10,000 cells by conventional imaging microscopy; |
· | enables characterization of specific cells within a heterogeneous cell population; |
· | manipulation and analysis of adherent and non-adherent living cells; and |
· | adding and rinsing reagents from living cells under observation. |
· | Clinical diagnostic / in vitro diagnostic market. Clinical diagnostic / in vitro diagnostic tests are essential to the practice of health care worldwide: In clinical diagnostics, a biological sample is taken from the patient and sent to a medical laboratory for analysis using reagents and instrument developed by the in vitro diagnostic (IVD) industry. A wide range of increasingly sophisticated diagnostic tests exist, and are used: |
· | Enzyme Kinetics. Enzyme kinetics is the study of the rates of chemical reactions that are catalyzed by enzymes. These studies provide insights into the catalytic mechanism of enzymes, their role in metabolism, how their activities are controlled within cells and how drugs and poisons can inhibit their activities. These studies are important because they help to explain how enzymes work and may predict how enzymes behave in living organisms. |
· | Cytokine measurements. Cytokines are extracellular signaling proteins or peptides that act as a local mediator in cell to cell communication. The communication involves regulating proliferation (division) and differentiation of cells. When these "social controls" on cell division fail, cancer and other diseases result and damage occurs to body tissues and organs. The study of cytokine reactions in cells plays an important role in understanding diseases and developing new drugs to combat them. |
· | Immunology. Immunology research on medical problems is becoming increasingly complex, focusing on the regulation and control of immune responses that involve cytokines, receptors, signaling and other biochemical processes. Vaccines developed as a result of this research need to be tested in vivo but studies in mice and other laboratory animals often cannot be directly extrapolated to humans because of biological differences. |
· | Generation I (CCI) - The following are the current product lines available for sales and marketing under the CKChip brand name offering to basic grid types A-20 for cells under 15 micrometer in size and A-50 for cells above 15 micrometer in size . |
o | Starter Kit - Including cell loader, cover-slips, holder unit, vacuum-pen, 8 CKChip units and our "WELLS" software |
o | CKChip-R - for upright and inverted fluorescence microscopy applications enabling repeated multi-live single cell monitoring, and multiple rinsing of reagents and continues rinsing in upright microscopes only. |
o | CKChip - I - for upright and inverted fluorescence microscopy applications enabling repeated multi-live single cell monitoring, and multiple rinsing of reagents and continues rinsing in inverted microscopes only. |
o | DynamiCa kit - A dedicated kit for Ca flux measurements offering a simple platform that facilitates microscopic analysis of transient intracellular calcium levels. |
o | WELLS Software - A dedicated CKChip image analysis software providing software tools for researchers using the CKChip. |
o | CKChip HM - for high magnification imaging. |
· | Generation II (CCT) - a transparent Cell Carrier that in addition to the features described above, is also suitable for light microscopy, reagent, chemical, and biological coating options. Subject to available funds, we are making an effort to introduce the first version of this product, which is in a development stage, during 2010. |
· | Generation III (CCM) - We expect the CCM will be offered with special kits to enable clinical diagnostic applications based on research currently in progress. We are currently performing feasibility test of the first clinical diagnostic application for the CCM. |
· | The academic community tends to operate in networks in which word of mouth supports the spread of a chosen technology; |
· | Academic researchers are considered early adopters of new technology, relative to clinicians, allowing them to expand their research capabilities; and |
· | There is strong scientific focus on cell-based applications. |
· | We have recently invested substantial efforts in developing our transparent cell carrier, which was a challenging objective that required a series of prototype development and investigation of various potential designs that met product definitions and allowed an economical production process. Due to budget constraints, however, we were required to limit our efforts and decided upon a preferred first product design which may not be optimal in performance. |
· | We have also invested efforts in studying and developing specific coating capabilities on the cell carrier in order to expand its potential applications and product line range. While we made initial steps to establish the foundation for potential future products incorporating specific coatings of reagents chemicals and antibodies on the Cell Carrier, this activity was limited due to budget constraints as well. |
· | The current software that accompanies our products provides image analysis of data acquired from the microscope. We are currently working on the definition and development of data analysis software to enhance the ability of scientists using the Cell Carrier to retrieve and analyze imagery data in a user friendly efficient way. |
· | We decided upon the first diagnostic clinical application to be developed based on our live cell monitoring ability. We are currently evaluating the feasibility of the protocol selected and we are also exploring means to optimize and establish stable test protocol. In order to facilitate this research activity we are collaborating with clinicians, although budget constraints have limited the process. |
· | An academic collaboration at the Berkeley campus of the University of California, which has developed a dynamic single cell culture array that, if commercialized, would directly compete with our current and future intended CKChip applications and products. |
· | SC World Inc., a Japanese biotechnology venture, that has been established to exploit micro-well cell chip technology that can capture lymphocyte cells for potential development of immunotherapeutic and immunodiagnostic tools. |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |